Back to discover
Drug

Mobocertinib

In clinical development
ClassEpidermal growth factor receptor erbB1 inhibitorEmerging researchEarly-to-mid development

Also known as Exkivity.

RxNorm2570736ChEMBLCHEMBL4650319ATCL01EB10UNII39HBQ4A67L
1
Research papers
1
Active clinical trials
Epidermal growth factor receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1/2 Study of the Oral EGFR/HER2 Inhibitor TAK-788 in Japanese Non-Small Cell Lung Cancer Patients

Clinical trial2026-05-14Results posted · ClinicalTrials.gov

A Phase 1 Study to Assess Absolute Bioavailability of TAK-788 and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]-TAK-788 in Male Healthy Subjects

Clinical trial2024-02-12Results posted · ClinicalTrials.gov

A Phase 1 Pharmacokinetic Study of Oral Mobocertinib in Subjects With Severe Renal Impairment and Normal Renal Function

Clinical trial2024-01-08Results posted · ClinicalTrials.gov

Phase 1 Pharmacokinetics and Safety Study of Oral Mobocertinib in Subjects With Moderate or Severe Hepatic Impairment and Normal Hepatic Function

Clinical trial2023-11-03Results posted · ClinicalTrials.gov

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

Research2021-12-16JAMA oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Mobocertinib
Aliases & brands
Exkivity
RxNorm CUI
2570736
ChEMBL ID
CHEMBL4650319
ATC codes
L01EB10
UNII
39HBQ4A67L
Primary mechanism
Epidermal growth factor receptor erbB1 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Epidermal growth factor receptor
EGFR · P00533
INHIBITOREpidermal growth factor receptor erbB1 inhibitor

Clinical trials

4 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
4
registered trials across all phases
LATEST COMPLETION 2022
1
Active studies
3
Completed
PHASE DISTRIBUTIONn = 4
Phase 14

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
Aniline Compounds1Carcinoma, Non-Small-Cell Lung1Indoles1Lung Neoplasms1Pyrimidines1
Journals, researchers & institutions
Top journals
  • JAMA oncology1
Leading researchers
  • Bunn V1
  • Felip E1
  • Garcia Campelo MR1
  • Griffin C1
  • Jänne PA1
  • Jin S1
  • Kim SW1
  • Kim TM1
Leading institutions
free-text, unnormalised
  • Asan Medical Center1
  • Complejo Hospitalario Universitario A Coruña Hospital Teresa Herrera-Materno Infantil1
  • Dana-Farber Cancer Institute1
  • Memorial Sloan Kettering Cancer Center1
  • National Taiwan University Cancer Center1
  • Seoul National University Hospital1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Platinum

Studied across 2 of the same disease areas as Mobocertinib in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials